For US residents only.
In BRAF+ Melanoma, Targeting the MAPK Pathway Can Alter the Tumor Microenvironment in a Way That Could Be Synergistic When Combined With PD-1 Blockade.
For additional information on melanoma clinical trials, please click here.
2/20 M-GON-1226454
You are now leaving the Novartis site and moving to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or click OK to continue.
